Organizers can borrow ideas from the business world about where to look for innovation, and how our movement ecology can make space for it.
NCCN updated its SCLC guidelines to recommend testing in patients with suspected PNS; however, researchers found uptake in the US is low.
A panelist discusses how lurbinectedin and tarlatamab both remain essential options within evolving treatment strategies.
LAG-3 is identified as a potential biomarker for SCLC, aiding in patient stratification for ICI therapy. Higher LAG-3 expression in SCLC correlates with improved survival and increased immune activity ...
Clinical Trials Arena on MSN
Ariceum Therapeutics doses first patient for SANTANA-225 trial for MCC and ES-SCLC
A riceum Therapeutics has announced the dosing of first patient in the SANTANA-225 Phase I/II clinical trial for 225Ac-SSO110 ...
Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage ...
ES-SCLC patients show limited benefit from 3L therapies, highlighting the need for novel treatments to improve outcomes. SCLC is aggressive, often diagnosed at an extensive stage, and treated with ...
IND application filed for MP0712, the Company's lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images ...
Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback